How to Donate
What is Fragile X?
Toward a Cure ... What's New?
Seaside Therapeutics Discontinues Fragile X Clinical Trials of STX209 (arbaclofen)
Company cites financial constraints
Results of Phase 2b Clinical Trial of Arbaclofen in Autism Spectrum Disorder are Disappointing
Seaside Therapeutics reports the study did not show improvement on the primary endpoint of social withdrawal, but it did demonstrate improvement on the Clinical Global Impression of Severity scale.
Experimental compound FRAX486 Reverses Signs of Fragile X in mice
Another FRAXA-funded research grant has borne fruit, and an experimental new PAK inhibitor called
is in the news.
FRAXA president & co-founder Katie Clapp on Diane Rehm Show
On Tuesday, 3/19,
The Diane Rehm Show
, a syndicated radio show, will discuss choosing efficient and effective charities.
Fragile X Research Grant Opportunities for Canadian scientists
Grants of $500,000 per year for five years to be funded by BrainCanada and the Azrieli Foundation
© 1999-2013 FRAXA Research Foundation, 10 Prince Place, Suite 203, Newburyport, MA 01950. Tax ID: 04-3222167.
Editor/writers: Katie Clapp, MS, and Michael Tranfaglia, MD. All rights reserved.
Site designed by:
Lilac Design Studio, LLC